NCT05932550View on ClinicalTrials.gov

Safety of Maraviroc for Post-stroke Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

August 4, 2022

Study Completion Date

August 4, 2022

Conditions
Post-stroke Depression
Interventions
DRUG

Maraviroc 300 mg

10 week treatment as add-on therapy to anti-depressants

Trial Locations (1)

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors
lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV

NCT05932550 - Safety of Maraviroc for Post-stroke Depression | Biotech Hunter | Biotech Hunter